Randomized Phase III Trial Comparing Everolimus Plus Placebo Versus Everolimus Plus Bevacizumab for Advanced Renal Cell Carcinoma Progressing After Treatment With Tyrosine Kinase Inhibitors.
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 05 Oct 2017
At a glance
- Drugs Bevacizumab (Primary) ; Everolimus (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 25 Feb 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 23 Nov 2012 New source identified and integrated (Barbara Ann Karmanos Cancer Institute; CALGB90802)